Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected

被引：0

作者：

Gallant, Joel ^{[1
]}

Brunetta, Jason ^{[2
]}

Crofoot, Gordon ^{[3
]}

Benson, Paul ^{[4
]}

Mills, Anthony ^{[5
]}

Brinson, Cynthia ^{[6
]}

Oka, Shinichi ^{[7
]}

Cheng, Andrew ^{[8
]}

Garner, Will ^{[8
]}

Fordyce, Marshall ^{[8
]}

Das, Moupali ^{[8
]}

McCallister, Scott ^{[8
]}

机构：

[1] Southwest CARE Ctr, 649 Harkle Rd,Ste E, Santa Fe, NM 87505 USA

[2] Univ Toronto, Family & Community Med, Toronto, ON, Canada

[3] Crofoot Res Ctr, Houston, TX USA

[4] Be Well Med Ctr, Berkley, MI USA

[5] Southern Calif Mens Med Grp, Los Angeles, CA USA

[6] Cent Texas Clin Res, Austin, TX USA

[7] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan

[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 73卷 / 03期

关键词：

tenofovir alafenamide; TAF; elvitegravir; HIV; HBV; coinfection; bone; renal; TENOFOVIR DISOPROXIL FUMARATE; HIV-INFECTED PATIENTS; CHRONIC HEPATITIS-B; ANTIRETROVIRAL-NAIVE; ABACAVIR-LAMIVUDINE; EMTRICITABINE; PHARMACOKINETICS; EFAVIRENZ; DENSITY;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B. We report the results of an open-label, noncomparative switch study evaluating the efficacy and safety of E/C/F/TAF in HIV/hepatitis B virus (HBV)-coinfected adults. At 48 weeks, 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA <50 copies/mL; HBV DNA <29 IU/mL). Seroconversion occurred in 2.9% of hepatitis B surface antigen-positive participants and in 3.3% of HBV e antigen-positive participants; 40% of those with abnormal alanine aminotransferase normalized. E/C/F/TAF was associated with improved renal function and reduced bone turnover. These data support the use of E/C/F/TAF in treating HIV/HBV coinfection.

引用

页码：294 / 298

页数：5

共 50 条

[11] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Stribild®): A Review of Its Use in the Management of HIV-1 Infection in Adults
Perry, Caroline M.
DRUGS, 2014, 74 (01) : 75 - 97
[12] A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
Wohl, David A.
Cohen, Calvin
Gallant, Joel E.
Mills, Anthony
Sax, Paul E.
DeJesus, Edwin
Zolopa, Andrew
Liu, Hui C.
Plummer, Andrew
White, Kirsten L.
Cheng, Andrew K.
Rhee, Martin S.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : E118 - E121
[13] Switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): effects on T-cell compartment and HIV reservoirs
Merlini, Esther
Cazzaniga, Federico
Casabianca, Anna
Orlandi, Chiara
Ancona, Giuseppe
Cogliandro, Viola
Tincati, Camilla
Bini, Teresa
Magnani, Mauro
Monforte, Antonella d'Arminio
Marchetti, Giulia
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
[14] Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection
Huang, Y-S
Lee, C-H
Lee, Y-T
Sun, H-Y
Liou, B-H
Yang, C-J
Liu, C-E
Tang, H-J
Lin, S-P
Cheng, C-Y
Cheng, S-H
Lu, P-L
Ho, M-W
Huang, S-H
Tsai, H-C
Hung, C-C
HIV MEDICINE, 2019, 20 : 292 - 293
[15] Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen
Brown, Kimberley
Thomas, David
McKenney, Kevin
Reeder, Michael
Simonson, Richard Bruce
Bicer, Ceyhun
Nettles, Richard E.
Crauwels, Herta
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (04): : 541 - 548
[16] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet for HIV-1 Infection Treatment
Olin, Jacqueline L.
Spooner, Linda M.
Klibanov, Olga M.
ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1671 - 1677
[17] Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial
Natukunda, Eva
Gaur, Aditya H.
Kosalaraksa, Pope
Batra, Jagmohan
Rakhmanina, Natella
Porter, Danielle
Shao, Yongwu
Zhang, Heather
Pikora, Cheryl
Rhee, Martin S.
LANCET CHILD & ADOLESCENT HEALTH, 2017, 1 (01): : 27 - 34
[18] Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
Gaur, Aditya H.
Kizito, Hilda
Prasitsueubsai, Wasana
Rakhmanina, Natella
Rassool, Mohammed
Chakraborty, Rana
Batra, Jagmohan
Kosalaraksa, Pope
Luesomboon, Wicharn
Porter, Danielle
Shao, Yongwu
Myers, Michael
Ting, Lillian
SenGupta, Devi
Quirk, Erin
Rhee, Martin S.
LANCET HIV, 2016, 3 (12): : E561 - E568
[19] Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)
Oliver Ackaert
David McDougall
Carlos Pérez-Ruixo
Juan Jose Pérez-Ruixo
John Jezorwski
Herta M. Crauwels
The AAPS Journal, 23
[20] Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)
Ackaert, Oliver
McDougall, David
Perez-Ruixo, Carlos
Perez-Ruixo, Juan Jose
Jezorwski, John
Crauwels, Herta M.
AAPS JOURNAL, 2021, 23 (04):

← 1 2 3 4 5 →